Biomarin Pharmaceutical Inc (BMRN) · Oct 6, 2026 · Guidance
$320M Alesta charges — ~$320M FY 2026 pre-tax charges; ~$1.55 EPS impact
BioMarin’s new guidance filing quantifies the Alesta acquisition’s $320M 2026 cost, masking the longer-term pipeline rationale with a near-term EPS hit.
BioMarin is expanding an already growing rare-disease platform: it is integrating the Amicus portfolio while building a skeletal-conditions pipeline that now includes ALE1, an early-stage oral hypophosphatasia candidate from Alesta. The Alesta transaction itself was already announced and closed before this filing, so the new information is primarily the financial magnitude and timing of the hit.
The near-term earnings impact is substantial. BioMarin expects roughly $283 million of acquired in-process research and development expense in the third quarter, reducing both GAAP and non-GAAP diluted EPS by approximately $1.50.
| Measure | Q3 2026 | FY 2026 |
|---|---|---|
| Pre-tax charges | ~$283M (acquired IPR&D) | ~$320M, including operating, transaction and transition costs |
| EPS impact | ~$(1.50) | ~$(1.55) |
| Guidance status | Not yet updated | Updated guidance expected with Q3 results |
This is not yet a formal guidance cut, but it makes the next update unavoidable. The August 6 full-year guidance excluded Alesta because the acquisition had not been completed, and BioMarin now says it will provide revised guidance alongside third-quarter results. 〔0〕 That leaves the underlying operating outlook unresolved rather than clearly worse: the filing quantifies acquisition accounting and integration costs, not a deterioration in demand or product performance.
The strategic rationale remains longer dated and unproven. Alesta adds ALE1 to BioMarin’s pipeline, but the asset is still in Phase 1/2a development, meaning the acquisition’s potential benefit is dependent on clinical progress rather than near-term revenue.
Bottom line: The filing turns a previously disclosed acquisition into a clearly defined 2026 earnings burden. It does not damage the core operating story by itself, but it creates a meaningful near-term EPS reset while the strategic payoff remains years away and uncertain.
Q3 results and updated FY 2026 guidance
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!